Crexont (IPX203) vs Melevodopa/carbidopa (Sirio)

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Parkinson's Disease

Shared mechanism: dopamine precursor · full Parkinson's Disease pipeline

Crexont (IPX203)

Marketed by Amneal Pharmaceuticals and partners

Approved in Parkinson's Diseasesmall molecule
Reliable signal

NCT03670953 · Phase 3 · completed

The study was randomized, quadruple-blind, double-dummy, and active-controlled, with 506 participants entering the randomized maintenance period and 495 contributing primary-endpoint data. The clinical primary endpoint was met: IPX203 produced a significantly greater improvement in daily “good on” time than immediate-release carbidopa-levodopa (p=0.0194).

Next expected readout: February 2027 · NCT07138560 (registry estimate)

Reported efficacy

Mean Change From Baseline in "Good on" Time Per Day at Week 20/Early Termination (ET) (Baseline (Week 7) and Week 20/ET): Mean Change From Baseline in "Good on" Time Per Day at Week 20/Early Termination (ET) (Baseline (Week 7) and Week 20/ET): IPX203 - Double-Blind Maintenance — Baseline (Week 7): 11.67 hours/day (Standard Deviation 2.943); Change at Week 20/ET: -0.39 hours/day (Standard Deviation 2.706) vs IR CD-LD - Double -Blind Maintenance — Baseline (Week 7): 11.72 hours/day (Standard Deviation 2.759); Change at Week 20/ET: -0.97 hours/day (Standard Deviation 3.081) (met)

Result source: NCT03670953

Melevodopa/carbidopa (Sirio)

Marketed by Chiesi Farmaceutici

Phase 1/2 in Parkinson's Diseasesmall molecule
Partial signal

NCT00491998 · Phase 1/2 · completed

The study was randomized and double-blind, with a planned enrollment of 27 participants and a comparison with standard levodopa/carbidopa tablets. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.

Reported efficacy

to characterise the plasma concentrations of L-dopa after repeated doses of V1512 in fluctuating PD patients compared to standard L-dopa/carbidopa (Sinemet) over the course of the day (4 weeks): L-dopa accumulation from first to final dose across Cohorts 1/2/3: mean AUC0-t increase V1512 51%/50%/85% vs standard L-dopa/carbidopa 92%/93%/150%; mean Cmax increase V1512 30%/14%/52% vs standard 64%/23%/99%. (not_applicable)

Result source: NCT00491998

Results for Parkinson's Disease

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointCrexont (IPX203)Melevodopa/​carbidopa (Sirio)
OFF time, change—Not reported—Not reported
ON time without troublesome dyskinesia, change—Not reported—Not reported
UPDRS Part III, change—Not reported—Not reported
MDS-UPDRS Part II, change—Not reported—Not reported

OFF time, change

Crexont (IPX203)
—Not reported
Melevodopa/​carbidopa (Sirio)
—Not reported

ON time without troublesome dyskinesia, change

Crexont (IPX203)
—Not reported
Melevodopa/​carbidopa (Sirio)
—Not reported

UPDRS Part III, change

Crexont (IPX203)
—Not reported
Melevodopa/​carbidopa (Sirio)
—Not reported

MDS-UPDRS Part II, change

Crexont (IPX203)
—Not reported
Melevodopa/​carbidopa (Sirio)
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

Melevodopa/carbidopa (Sirio)
L-dopa accumulation from first to final dose across Cohorts 1/2/3: mean AUC0-t increase V1512 51%/50%/85% vs standard L-dopa/carbidopa 92%/93%/150%; mean Cmax increase V1512 30%/14%/52% vs standard 64%/23%/99%. NCT00491998 · Phase 1/2 · design grade: moderate · publication or press release

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Crexont (IPX203): 2 of 4 rows · Melevodopa/carbidopa (Sirio): 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricCrexont (IPX203)
Dropout rate
—IPX203 - Dose Conversion
NCT03670953 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
show 1 more result
—IPX203 - Double-Blind Maintenance
NCT03670953 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
Discontinued due to AEs
—IPX203 - Dose Conversion
NCT03670953 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
show 1 more result
—IPX203 - Double-Blind Maintenance
NCT03670953 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
Serious AEs
2%IPX203 - Dose Conversion
NCT03670953 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
show 1 more result
3.1%IPX203 - Double-Blind Maintenance
NCT03670953 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
Most frequent reported AEs
dyskinesia 6.8%
nausea 4.9%
dry mouth 4.2%
NCT03670953 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
show 1 more result
nausea 4.3%
anxiety 2.7%
dizziness 2.3%
NCT03670953 · Phase 3 · monotherapy · Parkinson's Disease · phase 3

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Crexont (IPX203)

Good on" Time -0.39 vs -0.97 IR CD-LD per day @ 20wk
absolute change · per day
Change at Week 20/ET
NCT03670953 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
OFF-time 0.29 vs 0.76 IR CD-LD per day @ 20wk
absolute change · per day
Change at Week 20/ET
NCT03670953 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
PGI-C 29.7% (n=256) vs 18.8% (n=250) IR CD-LD @ 20wk
responder rate · % of participants
NCT03670953 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
MDS-UPDRS Part III 1.1 vs 0.9 IR CD-LD score @ 20wk
absolute change · score
Change at Week 20/ET
NCT03670953 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
MDS-UPDRS Part II III 2 vs 1.8 IR CD-LD score @ 20wk
absolute change · score
Change at Week 20/ET
NCT03670953 · Phase 3 · monotherapy · Parkinson's Disease · phase 3

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Crexont (IPX203)'s landscape · Melevodopa/carbidopa (Sirio)'s landscape